Estudo INSPIRIS China PMCF (INSPIRIS China)
Estudo de acompanhamento clínico pós-comercialização da válvula aórtica INSPIRIS RESILIA da Edwards Lifesciences na população chinesa
The objective of this post-market trial is to evaluate long term safety and performance of the Edwards Lifesciences INSPIRIS RESILIA aortic valve in Chinese patients in a real-world clinical setting.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
The trial is a multi-center, prospective, single-arm study that will implant up to 250 subjects with the Edwards INSPIRIS RESILIA aortic valve and will continue to follow and assess them after implant for 5 years. In an effort to obtain sufficient long-term data, all subjects will be asked to reconsent to extended follow-up through 10 years.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Contactos e Locais
Locais de estudo
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100037
- Fuwai Hospital, CAMS & PUMC
-
Beijing, Beijing Municipality, China, 100029
- Beijing Anzhen Hospital, Capital Medical University
-
-
Fujian
-
Xiamen, Fujian, China, 361008
- Xiamen Cardiovascular Hospital Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- The First Affiliated Hospital, Sun Yat-sen University
-
Shenzhen, Guangdong, China, 518038
- Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- The First Affiliated Hospital of Zhengzhou University
-
Zhengzhou, Henan, China, 450008
- Henan Provincial Chest Hospital
-
Zhengzhou, Henan, China, 451460
- Fuwai Central China Cardiovascular Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210012
- Nanjing First Hospital
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710065
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610072
- Sichuan Academy of Medical Sciences·Sichuan Provincial People's Hospital
-
-
Yunnan
-
Kunming, Yunnan, China, 650102
- Fuwai Yunnan Cardiovascular Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Subjects requiring an elective replacement of their native or prosthetic aortic valve who have agreed to participate in the study.
Descrição
Inclusion Criteria:
- Subject is 18 years or older
- Subjects requiring an elective replacement of their native or prosthetic aortic valve as indicated per the IFU
- Subject is scheduled to undergo planned aortic valve replacement with or without concomitant coronary bypass surgery, with or without ascending aorta replacement
- Provide signed informed consent prior to the study participation
Exclusion Criteria:
- Valve implantation is contraindicated per the IFU
- Requires planned multiple valve replacement/ repair
- Has active endocarditis/myocarditis prior to the scheduled aortic replacement surgery
- Estimated Life expectancy< 12 months
- Current or recent participation (within 6 weeks prior to surgery) in another drug or device trial
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Número de grupos/coortes
Coortes e Intervenções
Grupo / CoorteGrupo / Coorte |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
EDWARDS INSPIRIS RESILIA Aortic Valve
Subjects who were treated with the INSPIRIS RESILIA aortic heart valve. |
Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Subject's Occurrence Rate of Study Valve Related Death
Prazo: 10 Years
|
The primary safety endpoint is the percentage of study valve related death which includes death caused by structural valve deterioration, nonstructural dysfunction, valve thrombosis, embolism, bleeding event, or operated valve endocarditis; death related to reintervention on the operated valve; or sudden, unexplained death. |
10 Years
|
|
Subject's Occurrence Rate of Structural Valve Deterioration
Prazo: 10 Years
|
The primary safety endpoint is the percentage of Structural Valve Deterioration which includes dysfunction or deterioration involving the operated valve (exclusive of infection or thrombosis), as determined by re-operation, autopsy, or clinical investigation. |
10 Years
|
|
Subject's Occurrence Rate of Re-operation on the Study Valve
Prazo: 10 Years
|
The primary safety endpoint is the reoperation rate on the study valve which is any operation that repairs, alters, or replaces the study valve, which occurs after the completion of the procedure and the transfer out of the procedure room. |
10 Years
|
|
Subject's Occurrence Rate of Major Bleeding
Prazo: 10 Years
|
The primary safety endpoint is the rate of major bleeding which is any episode of major internal or external bleeding that causes death, hospitalization, or permanent injury (e.g. Vision loss) or necessitates transfusion of 3 or more units of PRBC, pericardiocentesis, or exploration/reoperation for bleeding. |
10 Years
|
|
Subject's Occurrence Rate of Thromboembolic Events
Prazo: 10 Years
|
The primary safety endpoint is the rate of thromboembolic events which is an embolic event that occurs in absence of infection (endocarditis) starting from anesthesia time. Embolism may be manifested by a neurologic event (Stroke or Transient Ischemic Attack) or a non-cerebral embolic event. |
10 Years
|
|
Subject's Occurrence Rate of Stroke
Prazo: 10 Years
|
The primary safety endpoint is the rate of strokes which is a prolonged (>72 hours) or permanent neurologic deficit that is usually associated with abnormal results of magnetic resonance imaging or computed tomographic scans. |
10 Years
|
|
Subject's Occurrence Rate of Transient Ischemic Attack
Prazo: 10 Years
|
The primary safety endpoint is the rate of transient ischemic attacks which is characterized by fully reversible symptoms of short duration. |
10 Years
|
|
Subject's Occurrence Rate of Non-Cerebral Thromboembolism
Prazo: 10 Years
|
The primary safety endpoint is the rate of non-cerebral thromboembolism which is an embolus documented operatively, at autopsy, or clinically that produces signs or symptoms attributable to complete or partial obstruction of a peripheral artery (does not include deep vein thrombosis). |
10 Years
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Subject's Average Mean Gradient at 10 Years
Prazo: 10 Years
|
Hemodynamic performance - Mean gradients as evaluated by echocardiography |
10 Years
|
|
Subject's Average Peak Gradient at 10 Years
Prazo: 10 Years
|
Hemodynamic performance - Peak gradients as evaluated by echocardiography |
10 Years
|
|
Subject's Average Effective Orifice Area at 10 Years
Prazo: 10 Years
|
Hemodynamic performance - Effective Orifice Area evaluated by echocardiography |
10 Years
|
|
Subject's Average Effective Orifice Area Index at 10 Years
Prazo: 10 Years
|
Hemodynamic performance - Effective Orifice Area Index evaluated by echocardiography |
10 Years
|
|
Amount of Aortic Central Regurgitation in Subjects at 10 Years
Prazo: 10 Years
|
Hemodynamic performance - Aortic central regurgitation evaluated by echocardiography |
10 Years
|
|
Amount of Aortic Paravalvular Regurgitation in Subjects at 10 Years
Prazo: 10 Years
|
Hemodynamic performance - Aortic paravalvular regurgitation evaluated by echocardiography |
10 Years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Hansong Sun, Professor, Chinese Academy of Medical Sciences, Fuwai Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
Outros números de identificação do estudo
- 2021-09
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data will not be available to other researchers.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .